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TNF-related weak inducer of apoptosis (TWEAK) belongs to the TNF superfamily, which 
expresses its biological effects in several tissues. Being a small pleiotropic cytokine, TWEAK 
is essentially involved in the regulation of cell death involving necrosis or apoptosis, differen-
tiation, angiogenesis, migration, proliferation, and upregulating the expression of key inflam-
matory cytokines. As a membrane anchored protein, TWEAK acts by binding to the fibroblast 
growth factor-inducible 14 (Fn14), which is typically a type I transmembrane protein (Bernardi 
et al., 2019). This is the only reported ligand to which TWEAK binds to. In addition, TWEAK, 
being a type II transmembrane protein, also clamps itself onto a soluble cytokine by a proprotein 
convertase enzyme, namely, furin. Therefore, TWEAK binds both its membrane-anchored and 
soluble isoforms to Fn14. TWEAK is a tripartite glycoprotein, which constitutes an extracellu-
lar transmembrane domain, C-terminal region, and an intracellular region N-terminal (Claus et 
al., 2018). Fn14, thus, carries the extracellular TWEAK region, as well as, the cytoplasmic tail 
domain which is necessary for signal transduction. TWEAK–Fn14 expression is primarily lo-
cated in weakened cells and also in certain conditions involving inflammation and cancers, 
introducing several downstream signaling channels to reshape these tissues (Dwyer et al., 
2020). 
TWEAK-Fn14 expression is limited in normal tissues, but is highly expressed in other tu-
morous conditions and generally in cancer cells. There is an overexpression of this TWEAK 
system in the ovarian, esophageal, liver, bladder, lung, breast, prostate, colorectal and pancre-
atic cancers. Increased Fn14 expression is also reported in neuroblastoma, brain glioma and 
melanoma. Furthermore, several studies have also suggested strong display of Fn14 in breast 
metastases, non–small cell lung, melanoma, colorectal, and prostate cancers (El-Taweel et al., 
2020a). Fn14 overexpression is correlated primarily with advanced tumor stage and poor clin-
ical findings. 
Fn14 works on cells by triggering the binding of several adapter molecules to downstream 
molecules thereby causing transduction of signals. The TNF receptor associated factors (TRAF) 
family contains a variety of essential adapter molecules, which of these are connected to Fn14 
and downstream signaling paths (El-Taweel et al., 2020b). TRAFs 1-5 have been reported to 
bind to the cytoplasmic Fn14 tail. The anti-apoptotic protein, TRAF2 binding to Fn14 triggers 
the activation of NF-κB pathway, which in turn induces several cellular responses. The cellular 
inhibitor of apoptosis protein 1 (cIAP1) sensitizes various cells to TNF-α and turns on the sig-
nals of NF-κB. The presence of TWEAK/Fn14 facilitates the lysosomal degradation of cIAP1–
TRAF2, and then sensitizes the TNF-α-induced death immortalized tumor cells (Hu et al., 
2017). However, this mechanism is resistant to primary cells. The functional mechanisms in 
these two cell types could differ in various ways, as TNF-α controls the cell cycle by connecting 
it to one of the 2 receptors; TNFR (1 or 2). TNFR1 may contribute to cell death, whereas, 
TNFR2 facilitates the division of cells. 
NF-κB induces the production of chemokines, cytokines, metalloproteases and adhesion 
molecules. This constitutes the key inflammatory pathway leading to the growth and progres-
sion of cancer. The signaling of TWEAK/Fn14 triggers all the available alternate NF-κB path-
ways (Leng et al., 2011). The standard NF-κB pathway is defined by the NF-κB receptor phos-
phorylation and the p50/p65 heterodimers nuclear translocation, whereas, the alternative NF-
kB pathway is stimulated by kinase-inducing NF-κB stabilization and the translocation of het-
erodimers p52/RelB and p100 into the nucleus. Activity of the TWEAK-stimulated glioblas-
toma cell invasion is responsible for the NF-κB pathway and the NF-κB active kinase. More- 
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over, TWEAK/Fn14 activates non-canonic NF-κB signals, but it does reveal two distinct find-
ings for melanoma and prostate cancer cells, which are cell invasiveness prevention and stim-
ulation (Liu et al., 2019). 
Signaling from TWEAK/Fn14 has closely associated multiple biological tumors. Thus, 
TWEAK and Fn14 may be used as biomarkers for cancer projections and forecasts. Fn14 is 
exaggerated in primary breast carcinomas and plays a significant role in the prediction of brain 
metastasis, with strong specificity. One of the critical observations is that mice with breast car-
cinoma and brain metastasis, when treated, increased longevity and demonstrated a marked 
decrease in the production of TWEAK and Fn14 in tumors. Interestingly, the protein Fn14 is 
linked to human tumor glioma (Liu et al., 2017). The expression of Fn14 is also a significant 
prediction element in peptic, non-small cell lung cancers, carcinoma and hepatocellular disor-
der. Higher TWEAK serum rates are correlated with a locoregional deficiency in patients with 
squamous cell cancer in the neck and head regions, and large expression ratio of 
CD136/TWEAK in cancer is often associated to weak prognosis. Despite their elevated expres-
sion and frequent intervention correlated with tumors, TWEAK and Fn14 are also suitable can-
didates for tumor therapy (Liu et al., 2016). 
A variety of agents aiming at TWEAK or Fn14 were developed in the last decade. They 
achieved anti-tumor impact via three mechanisms; soluble TWEAK neutralization, Fn14 sig-
nal-blockade, and explicit Fn14-mediated tumor cell destruction. RG7212, a monoclonal neu-
tralizing antibody (mAb) which targets TWEAK, may block TWEAK/Fn14 signaling and pre-
vents solid tumor development in patients. RG7212 suppressed TWEAK/Fn14 signaling in pre-
clinical studies and showed activation of NF-κB (Martin-Sanchez et al., 2018). Secretion of 
cytokines in the cultured tumor cells and in murine models also inhibited the development of 
tumors. The findings from a Phase I study which was published recently, demonstrated that 
RG7212 has outstanding tolerability and a good pharmacokinetic profile when systemically 
administered. In colon cancer mice model, P2D10, anti-TWEAK antibody is shown to decrease 
diarrhoea induced by 5-Fluorouracil without affecting the anti-tumor effect of 5-Fluorouracil. 
GrB–TWEAK and GrB–Fc–IT4 are the 2 extremely effective systems with pro-apoptotic serine 
protease GrB. GrB–TWEAK is made up of the human-binding Fn14 domain as the targeting 
moiety and GrB–Fc–IT4 is made from a humanized single-chain antibody with Fn14 targeting 
(El-Taweel  et al., 2020a). They have also shown affinity and cytotoxicity toward Fn14-medi-
ated liver cancer and tumor prevention in vivo. Furthermore, they are fully human made and do 
not induce patient’s immune response. Some of the Fn14-specific antibodies include, 18D1, 
PDL192, and BIIB036. They have proven to decrease tumor growth in vivo by different meth-
ods, that include, Fn14 blockade, TWEAK–Fn14 engagement inhibition, and cause cellular 
cytotoxicity based on an antibody (ADCC). PDL192 and BIIB036 have demonstrated remark-
able in vivo efficacy, that is at least partially mediated by ADCC and due to the amplification 
of NF-κB signals. Therefore, the NF-κB pathway is stimulated by BIIB036. It also triggers IL-
8 production and causes the destruction of human cancerous cells. The 19D2 antibody prevents 
cancer development of RENCA cells primarily by ADCC (Zhang et al., 2020). The findings of 
a Phase I clinical trial suggested that, PDL 192 expressed severe liver and pancreatic medication 
toxicities at therapeutic dosage levels. These findings warrant further detailed clinical research, 
which is essentially required to evaluate the protection and efficacy of the Fn14-specific mon-
oclonal antibodies (Fn14 mAbs) (Xu et al., 2016). 
The signaling system of TWEAK/Fn14 is active in tumor pathogenesis. It plays a significant 
role in the development of cancer cells, their proliferation and invasion. TWEAK/Fn14 activa-
tion often stimulates downstream signals to control several primary events correlated with tu-
mor proliferation, angiogenesis and EMT. Furthermore, Fn14 may also be an indicator for tu-
mor growth. 
EXCLI Journal 2021;20:232-235 – ISSN 1611-2156 




Conflict of interest 
The authors declare no conflict of interest. 
 
REFERENCES 
Bernardi S, Voltan R, Rimondi E, Melloni E, Milani D, 
Cervellati C, et al. TRAIL, OPG, and TWEAK in kid-
ney disease: Biomarkers or therapeutic targets? Clin 
Sci (Lond). 2019;133:1145-66. 
Claus M, Herro R, Wolf D, Buscher K, Rudloff S, 
Huynh-Do, et al. The TWEAK/Fn14 pathway is re-
quired for calcineurin inhibitor toxicity of the kidneys. 
Am J Transplant. 2018;18:1636-45.  
Dwyer BJ, Jarman EJ, Gogoi-Tiwari J, Ferreira-Gon-
zalez S, Boulter L, Guest RV, et al. TWEAK/Fn14 sig-
nalling promotes cholangiocarcinoma niche formation 
and progression. J Hepatol. 2020; epub ahead of print. 
doi:10.1016/j.jhep.2020.11.018. 
El-Taweel AEI, Abdelrahman AMN, Sabry S, Salem 
RM. Serum TWEAK: A cutoff between segmental and 
nonsegmental vitiligo. J Cosmet Dermatol. 2020a; 
epub ahead of print. doi:10.1111/jocd.13644. 
El-Taweel AEI, Salem RM, Abdelrahman AMN, Mo-
hamed BAE. Serum TWEAK in acne vulgaris: An un-
known soldier. J Cosmet Dermatol. 2020b;19:514-8.  
Hu G, Zeng W, Xia Y. TWEAK/Fn14 signaling in tu-
mors. Tumour Biol. 2017;39:216-7. 
Leng RX, Pan HF, Qin WZ, Wang C, Chen LL, Tao J, 
et al. TWEAK as a target for therapy in systemic lupus 
erythematosus. Mol Biol Rep. 2011;38:587-92.  
Liu J, Liu Y, Peng L, Li J, Wu K, Xia L, et al. 
TWEAK/Fn14 signals mediate burn wound repair. J 
Invest Dermatol. 2019;139:224-34.  
Liu Q, Xiao S, Xia Y. TWEAK/Fn14 activation partic-
ipates in skin inflammation. Mediators Inflamm. 2017; 
2017:6746870. 
Liu YP, Yuan CM, Zhang SG, Hao QH, Wang MM, 
Zhang Z, et al. TWEAK/Fn14 signaling: a promising 
target in intervertebral disc degeneration. Histol Histo-
pathol. 2016;31:943-8.  
Martin-Sanchez D, Fontecha-Barriuso M, Carrasco S, 
Sanchez-Niño MD, Mässenhausen AV, Linkermann 
A, et al. TWEAK and RIPK1 mediate a second wave 
of cell death during AKI. Proc Natl Acad Sci U S A. 
2018;115:4182-7.  
Xu WD, Zhao Y, Liu Y. Role of the TWEAK/Fn14 
pathway in autoimmune diseases. Immunol Res. 2016; 
64:44-50.  
Zhang Y, Zeng W, Xia Y. TWEAK/Fn14 axis is an im-
portant player in fibrosis. J Cell Physiol. 2020; epub 
ahead of print. doi:10.1002/jcp.30089. 
 
 
